Blackstone related stories
All articles and analysis
Side Letter: What we know about Ben Meng's departure from CalPERSWe're all about CalPERS today. The world's eighth biggest private equity investor is dealing with the hasty departure of CIO Ben Meng. As details trickle out about the reasons why Meng left, the plan to push the giant pension further into private assets is being overshadowed. Here's today's brief, for our valued subscribers only.
Side Letter: GCM Grosvenor SPAC, family office merger, Blackstone GP interestsA new listed private equity heavyweight is on its way: GCM Grosvenor has $20bn in PE AUM and will soon be listed on NASDAQ. Here's today's brief, for our valued subscribers only.
Blackstone raises $3.5bnThe New York investment firm has raised capital for its diversified buyout vehicle.
Keep an eye on KentuckyA lawsuit involving Blackstone and KKR’s hedge fund businesses could have a bearing on wider private markets.
Side Letter: Ardian's impact rethink, Tikehau's haul, PE political donationsArdian is rethinking impact, PE pros are backing the Dems and capital keeps getting raised. Here's today's brief, for our valued subscribers only.
Side Letter: TPG targets secondaries, GIC results, HNWIs betting on unicornsThe secondaries market slowed right down in H1, but that won't dissuade private equity's mega firms – TPG, for example – from trying to break into that market. Here's today's brief, for our valued subscribers only.
BlackRock expects alternatives boost from wealth channelThe investment giant estimates capital commitments from private wealth investors will make up close to a fifth of its alternatives assets by year-end, says alternatives chief Edwin Conway.
Side Letter: Blackstone valuations, CPPIB's sustainability shift, deceptive dataCPPIB, the biggest private equity investor in the world according to our Global Investor 100, is going further on ESG. It won't be the only institution doing so, says a bfinance survey. Plus more on a topic as old as PE itself: problems with performance calculation.
Five questions with Blackstone Life Sciences’ Nicholas GalakatosThe newly formed investment arm leveraged the full power of Blackstone for its $4.6bn fundraise, and continues to do so as it deploys the fund.
LACERA mulls GP stakes opportunityVersus investing as an LP in PE funds, LACERA could benefit from regular and stable cashflows and the growth of GPs if it gets into the GP stakes market, according to a staff review in July.